Moderate to severe symptoms of benign prostatic hyperplasia (BPH). Reduction in the risk of acute urinary retention (AUR) & surgery in patients w/ moderate to severe BPH symptoms. Not approved for prevention of prostate cancer.
View Duodart overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Take approx 30 min after the same meal each day. Swallow whole, do not chew/open.
Contraindications
Hypersensitivity to dutasteride, other 5α-reductase inhibitors, tamsulosin, soya or peanut. History of orthostatic hypotension. Severe hepatic impairment. Women, childn & adolescents.
Regular evaluation of PSA values for possible risk of prostate cancer is encouraged. Perform digital rectal examination & other evaluations for prostate cancer or other conditions which can cause the same symptoms as BPH prior to initiation, & periodically thereafter. Risk of cardiac failure & CHF; breast neoplasia; hypotension (orthostatic or symptomatic); intraoperative floppy iris syndrome (IFIS) during cataract surgery. Concomitant use w/ CYP3A4 & CYP2D6 inhibitors. Contains sunset yellow (E110). Impaired ability to drive & use machines due to possible occurrence of dizziness. End stage renal disease (CrCl <10 mL/min). Mild to moderate hepatic impairment. Possible effect on male fertility. Women, childn & adolescents must avoid contact w/ leaking cap.
G04CA52 - tamsulosin and dutasteride ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Sign Out
